HCW Biologics Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 0/6
HCW Biologics has a total shareholder equity of $-6.3M and total debt of $10.0M, which brings its debt-to-equity ratio to -159.1%. Its total assets and total liabilities are $26.8M and $33.1M respectively.
Anahtar bilgiler
-159.1%
Borç/özkaynak oranı
US$10.02m
Borç
| Faiz karşılama oranı | n/a |
| Nakit | US$1.16m |
| Eşitlik | -US$6.30m |
| Toplam yükümlülükler | US$33.12m |
| Toplam varlıklar | US$26.82m |
Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: HCWB has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Uzun Vadeli Yükümlülükler: HCWB has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: HCWB has negative shareholder equity, which is a more serious situation than a high debt level.
Borcun Azaltılması: HCWB's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Bilanço
Nakit Pist Analizi
Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.
İstikrarlı Nakit Pisti: HCWB has less than a year of cash runway based on its current free cash flow.
Tahmini Nakit Akışı: HCWB has less than a year of cash runway if free cash flow continues to reduce at historical rates of 31.2% each year